tasly 1 billion upgrades target to US market

Tasly intends to raise capital to establish a modern Chinese medicine export production base, Chinese herbal medicine into the United States market. Today, tasly issued a directional additional scheme. The company intends to issue no more than 40 million shares, not less than 20 million shares, to a specified target of not more than 10 persons, with a minimum of 26.73 yuan/share. The funds collected are mainly used in 7 projects, including the main product compound Danshen drop pill expansion project, the modern Chinese Medicine solid preparation expansion construction project, the modern Chinese Medicine Resources Limited Company GMP Technical renovation project, 37 medicinal material reserve and planting base construction project as well as research and development, logistics, information system construction.　　7 Total projects are to be funded 1 billion yuan. In the compound Danshen drop pill expansion project, the total investment of 98.53 million yuan tasly modern Chinese medicine export production Base integrated control construction project is worthy of attention. It is announced that the project is intended to build a modern Chinese medicine production workshop in line with cGMP.　　The main products of the project are compound danshen dripping pill capsule preparation, the project reaches the postpartum production capacity of 160 million capsules/year, mainly used to meet the needs of compound danshen dripping pill FDA three clinical trial and cGMP certification, compound danshen dripping pill into the United States and European mainstream market after the initial market demand. Compound danshen dripping pill for coronary heart disease, angina pectoris and other cardiovascular disease treatment, is tasly flagship products, seven consecutive years of domestic sales breakthrough 1 billion yuan. 2009 to achieve sales revenue of nearly 1.2 billion yuan, accounting for the company's pharmaceutical industry income of 75%. In 2009, the pharmaceutical industry contributed 91% of the main profits to tasly. The company said that the compound danshen dripping pill became China's first Chinese herbal medicine, the world's first treatment of cardiovascular and cerebrovascular diseases of the compound herbal preparations through the FDA IND drugs, now as drug status into Russia, Canada, the Philippines and other 13 countries and regions. At present, the clinical trial of compound danshen dripping pill has been completed, and the clinical trial of Ⅲ period is being actively prepared.　　The construction period of this project is 33 months, from April 2010 to December 2012. In addition, in this project, the annual output of 8 billion tablets of compound danshen dripping pill, qi ginseng Yiqi Drop pill Expansion project is worthy of concern. Project construction period is 18 months, from October 2010 to March 2012.　　Company's existing drop pill formulations production lines in 1999 construction, design capacity of 9.6 billion tablets per year, still unable to meet the company's future rapid development needs. In addition, the company intends to raise more than 100 million yuan, for 37 medicinal materials reserves and planting base construction projects. Project is located in Wenshan City, Yunnan Province, in accordance with the gap required to build 1080 MU 37 varieties seedling base and 5400 Mu 37 production base. The project will also be phased in the use of some funds reserve 37 of 100 tons of medicinal materials. The base will be mainly used to meet the company's existing product capacity expansion and the development of new products on the demand for raw materials.